Jones Trading Upgrades Capricor Therapeutics to Buy, Announces $25 Price Target
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsUpgradesPrice Target
Jones Trading analyst Catherine Novack upgrades Capricor Therapeutics (NASDAQ:CAPR) from Hold to Buy and announces $25 price target.
Jones Trading analyst Catherine Novack upgrades Capricor Therapeutics (NASDAQ:CAPR) from Hold to Buy and announces $25 price target.